Selected Publications

Chen J., Ormes J.D., Higgins, J.D., Taylor, L.S.: Impact of surfactants on the crystallization of aqueous suspensions of celecoxib amorphous solid dispersion spray dried particles. Mol Pharm 12(2): 533-541, 2015.

Chen J., Mosquera-Giraldo, L.I., Ormes, J., Higgins, J.D., Taylor, L.S.: Bile Salts as Crystallization Inhibitors of Supersaturated Solutions of Poorly Water-Soluble Compounds. Crystal Growth & Design 15(6): 2593-2597, 2015.

Nofsinger, R.; Clas, S-D; Sanchez, R. I.; Walji, A; Balsells, A.; Dang, Q.; Hafey, M.; Wang, J.; Higgins, J.; Coleman, P.; Grobler, J.; Smith, R.; Wu, Y.: Design of prodrugs to enhance colonic absorption by increasing lipophilicity and blocking ionization. Pharmaceuticals 7: 207-219, 2014.

Mike McNevin and John Higgins: Discovering and Developing Molecules with Drug-Like Properties: Strategies and Methods for Drug Candidate Phase Optimization in Drug Discovery Space. Springer. Templeton, A.C., Byrn, S.R., Haskell, R.J., Prisinzano, Th.E. (eds.). Page: 209-240, 2014.

Higgins, John D. and Rocco, William: Preformulation: A stop along the drug development highway. Today’s Chemist 2013 Notes: Commentary.

Wuelfing, W.P., Kwong, E., and Higgins, J.: Identification of suitable formulations for high dose oral studies in rats using in vitro solubility measurements, the maximum absorbable dose model, and historical data sets. Mol Pharm 9(5): 1163-1174, 2012.

Higgins, J., Cartwright, M. and Templeton, A.: Progressing preclinical drug candidates: strategies on preclinical safety studies and the quest for adequate exposure. Drug Discovery Today 17(15-16): 828-836, 2012.

Kwong E, Higgins J, Templeton AC.: Strategies for Bringing Drug Delivery Tools into Discovery. International Journal of Pharmaceutics 412: 1-7, 2011.

Palucki, M., Higgins, J., Templeton, A. and Kwong, E.: Early Optimization of the Solid State Phase and Preclinical Toxicology Formulation for Potential Drug Candidates. J. Med. Chem. 53(16): 5897-5905, 2010.

Higgins, John D: Perspectives on preformulation programs at the discovery-development interface. American Pharmaceutical Review 12(3): 42-46, 2009.